These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 368764)

  • 1. [Effectiveness of pyridinolcarbamate in the overall treatment of infiltrative and cavernous-fibrous pulmonary tuberculosis].
    Makinskiĭ AI; Safarov RN; Fondaminskaia LD; Semenova AS; Fedotova NN
    Probl Tuberk; 1979 Jan; (1):26-30. PubMed ID: 368764
    [No Abstract]   [Full Text] [Related]  

  • 2. [The pyridinolcarbamate-clofibrate combination in the treatment of vascular diseases in diabetics].
    Parodi FA; Caputo G
    Clin Ter; 1976 Dec; 79(6):571-81. PubMed ID: 1009761
    [No Abstract]   [Full Text] [Related]  

  • 3. [Use of prodectin in pulmonary tuberculosis].
    Safarov RN; Makinskiĭ AI
    Vrach Delo; 1981 Nov; (11):83-4. PubMed ID: 7342450
    [No Abstract]   [Full Text] [Related]  

  • 4. [Use of the antikinin preparation prodectin in the complex treatment of pulmonary tuberculosis patients].
    Keleberda KIa; Svistunova AS; Kaminskaia GO; Kordonskaia VM
    Probl Tuberk; 1982 Oct; (10):42-5. PubMed ID: 7178102
    [No Abstract]   [Full Text] [Related]  

  • 5. [The importance of pyridinolcarbamate and clofibrate association in the treatment of arteriosclerosis].
    Pola P
    Minerva Cardioangiol; 1975 Apr; 23(4):261-9. PubMed ID: 1095958
    [No Abstract]   [Full Text] [Related]  

  • 6. [The importance of pyridinolcarbamate and clofibrate association in the treatment of arteriosclerosis].
    Pola P
    J Pharm Sci; 1975 Jan; 64(1):261-9. PubMed ID: 1094102
    [No Abstract]   [Full Text] [Related]  

  • 7. [Late results of the pyridinolcarbamate treatment of thrombotic obliterating arterial diseases of the extremities].
    Fisanovich TI; Tolstova LG
    Khirurgiia (Mosk); 1979 Sep; (9):76-80. PubMed ID: 502312
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pyridinolcarbamate (anginin) in the treatment of diabetic angiopathies].
    Tirkina TN; Aleksandrova LM; Kliachko VR; Mazovetskiĭ AG
    Ter Arkh; 1974; 46(1):107-10. PubMed ID: 4453966
    [No Abstract]   [Full Text] [Related]  

  • 9. [Influence of pyridinolcarbamate on platelet aggregation in diabetic subjects with ischemic cardiopathy].
    Citarrella P; Abbadessa V; Pecorella M; Cajozzo A
    Boll Soc Ital Cardiol; 1977; 22(7):1036-41. PubMed ID: 618239
    [No Abstract]   [Full Text] [Related]  

  • 10. Pyridinolcarbamate in the long-term treatment of ischaemic heart disease.
    Gulyás A; Szám I
    Ther Hung; 1976; 24(2):63-6. PubMed ID: 982341
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical evaluation of pyridinolcarbamate effect on patients with obliterating atherosclerosis (author's transl)].
    Roztocil K; Oliva I; Linhart J; Prerovský I; Modr Z
    Cas Lek Cesk; 1976 Aug; 115(33-34):1051-5. PubMed ID: 975177
    [No Abstract]   [Full Text] [Related]  

  • 12. [Evaluation of the effectiveness of anginine treatment of diabetic microangiopathies].
    Spesivtseva VG; Frenkel' VKh; Mamaeva GG; Sokolovskiĭ GA; Kukes VG
    Sov Med; 1975 Jul; (7):42-5. PubMed ID: 1216049
    [No Abstract]   [Full Text] [Related]  

  • 13. The use of prodectin in the treatment of cerebral arteriosclerosis and its complications.
    Abrányi I; Máté
    Ther Hung; 1976; 24(1):20-3. PubMed ID: 790631
    [No Abstract]   [Full Text] [Related]  

  • 14. [Indications for using antikinin preparations and blood kinin system activators in the combined treatment of pulmonary tuberculosis].
    Makinskiĭ AI
    Probl Tuberk; 1981 Oct; (10):33-7. PubMed ID: 7312848
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of arteriosclerotic peripheral chronic obliterating arteriopathies (A.P.C.O.) of the lower extremities with a new pharmacologic combination].
    Bagliani A; Borri P; Parravicini R
    Minerva Cardioangiol; 1975 Nov; 23(11):701-10. PubMed ID: 1223674
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effect of parmidin on the course of tuberculosis under isoniazid therapy].
    Solov'eva IP; Makinskiĭ AI
    Vrach Delo; 1984 Sep; (9):70-3. PubMed ID: 6390963
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of pyridinolcarbamate after acute and chronic administration in patients with atherosclerosis obliterans.
    Roztocil K; Oliva J; Linhart J; Prerovský I; Modr Z
    Int J Clin Pharmacol Biopharm; 1977 Mar; 15(3):135-8. PubMed ID: 844932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic results with combination of pyridinolcarbamate and clofibrate in atherosclerotic patients].
    Valiensi M; Riboli E; Lombardi M
    Minerva Cardioangiol; 1976 Feb; 24(2):148-54. PubMed ID: 1256654
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of Prodectin (pyridinolcarbamate) treatment of the circulation rate in obliterating arterial diseases of the lower extremities.
    Fényes G; Gótzy G; Fehrentheil L
    Ther Hung; 1975; 23(2):64-66. PubMed ID: 1188705
    [No Abstract]   [Full Text] [Related]  

  • 20. A multiclinic double-blind trial of pyridinolcarbamate and inositol niacinate in ischemic ulcer due to chronic arterial occlusion.
    Mishima Y; Kamiya K; Sakaguchi S; Kusaba A; Sakuma A
    Angiology; 1977 Feb; 28(2):84-94. PubMed ID: 326097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.